The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality
Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Lisset Hermida(Centro de Ingeniería Genética y Biotecnología), Vivian Huerta(Centro de Ingeniería Genética y Biotecnología), Edith Suzarte(Centro de Ingeniería Genética y Biotecnología), Yasser Perera(Construction Development (Qatar)), Panchao Ai(Zhejiang Yongning Pharma (China)), Gerardo Guillén(Hunan City University), Ke Yang(Army Medical University), A.M. Martin(Institut thématique Génétique, génomique et bioinformatique), Ricardo Silva(Centro de Ingeniería Genética y Biotecnología), Rong Chen(Shanghai Jiao Tong University), Changyuan Tan(Zhejiang Yongning Pharma (China)), Alexis Musacchio(Instituto Cajal), Laura Lazo(Centro de Ingeniería Genética y Biotecnología)
Cited by 11
Related Papers
SARS-CoV-2 cell tropism and multiorgan infection
|Cell Discovery|2021|241
Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis Sieb. et Zucc
|Journal of Ethnopharmacology|2017|189
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153